Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts

Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma

Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807

MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma

Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405

Glioma Stem Cell Lines Expanded in Adherent Culture Have Tumor-Specific Phenotypes and Are Suitable for Chemical and Genetic Screens

Pollard, S. M., Yoshikawa, K., Clarke, I. D., Danovi, D., Stricker, S., Russell, R., Bayani, J., Head, R., Lee, M., Bernstein, M., et al. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.03.014 · Cited by 1,025

MGMT: its role in cancer aetiology and cancer therapeutics

Gerson, S. L. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1319 · Cited by 817

Correlation of O 6 -Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity

Hegi, M. E., Liu, L., Herman, J. G., Stupp, R., Wick, W., Weller, M., Mehta, M. P., & Gilbert, M. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5964 · Cited by 811

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

Weller, M., Stupp, R., Reifenberger, G., Brandes, A. A., van den Bent, M. J., Wick, W., & Hegi, M. E. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.197 · Cited by 803

Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide

Hegi, M. E., Diserens, A., Godard, S., Dietrich, P.-Y., Regli, L., Ostermann, S., Otten, P., van Melle, G., de Tribolet, N., & Stupp, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0384 · Cited by 782

Clinical Relevance of MGMT in the Treatment of Cancer

Gerson, S. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.110 · Cited by 429

MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance

Yip, S. S. F., Miao, J., Cahill, D. P., Iafrate, A. J., Aldape, K., Nutt, C. L., & Louis, D. N. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3012 · Cited by 413

Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts

Kitange, G. J., Carlson, B. L., Schroeder, M. A., Grogan, P. T., Lamont, J. D., Decker, P. A., Wu, W., James, C. D., & Sarkaria, J. N. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-090 · Cited by 387

Glioblastoma multiforme: Pathogenesis and treatment

Alifieris, C. E., & Trafalis, D. T. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.005 · Cited by 859

MGMT testing—the challenges for biomarker-based glioma treatment

Wick, W., Weller, M., van den Bent, M. J., Sanson, M., Weiler, M., von Deimling, A., Plass, C., Hegi, M. E., Platten, M., & Reifenberger, G. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.100 · Cited by 599

The p53 Pathway in Glioblastoma

Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440

DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma

Lu, C., Wei, Y., Wang, X., Zhang, Z., Yin, J., Li, W., Chen, L., Lyu, X., Shi, Z., Yan, W., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-1137-5 · Cited by 303

Poised epigenetic states and acquired drug resistance in cancer

Brown, R., Curry, E., Magnani, L., Wilhelm-Benartzi, C. S., & Borley, J. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3819 · Cited by 301

Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response

Hombach‐Klonisch, S., Mehrpour, M., Shojaei, S., Harlos, C. H., Pitz, M. W., Hamaï, A., Siemianowicz, K., Likus, W., Wiecheć, E., Toyota, B. D., et al. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.017 · Cited by 298

A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma

Chen, X., Zhang, M., Gan, H., Wang, H., Lee, J., Fang, D., Kitange, G. J., He, L., Hu, Z., Parney, I. F., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05373-4 · Cited by 270

Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p

Wu, P., Cai, J., Chen, Q., Han, B., Meng, X., Li, Y., Li, Z., Wang, R., Lin, L., Duan, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10025-2 · Cited by 183

The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma

Goenka, A., Tiek, D., Song, X., Huang, T., Hu, B., & Cheng, S.-Y. (2021) · Cells · doi:10.3390/cells10030484 · Cited by 169

A predictive microfluidic model of human glioblastoma to assess trafficking of blood–brain barrier-penetrant nanoparticles

Straehla, J. P., Hajal, C., Safford, H. C., Offeddu, G. S., Boehnke, N., Dacoba, T. G., Wyckoff, J. B., Kamm, R. D., & Hammond, P. T. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2118697119 · Cited by 164

Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review)

Cabrini, G., Fabbri, E., Nigro, C. L., Dechecchi, M. C., & Gambari, R. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3026 · Cited by 144

The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma

Banelli, B., Carra, E., Barbieri, F., Würth, R., Parodi, F., Pattarozzi, A., Carosio, R., Forlani, A., Allemanni, G., Marubbi, D., et al. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1090063 · Cited by 135

DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme

Nagel, Z. D., Kitange, G. J., Gupta, S. K., Joughin, B. A., Chaim, I. A., Mazzucato, P., Lauffenburger, D. A., Sarkaria, J. N., & Samson, L. D. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1151 · Cited by 131

Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma

Gupta, S. K., Kizilbash, S. H., Carlson, B. L., Mladek, A. C., Boakye‐Agyeman, F., Bakken, K. K., Pokorny, J. L., Schroeder, M. A., Decker, P. A., Cen, L., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv369 · Cited by 128

Epigenetic modulation of metabolism in glioblastoma

Dong, Z., & Cui, H. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.09.002 · Cited by 119

Epigenetic Targeting of Glioblastoma

Romani, M., Pistillo, M. P., & Banelli, B. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00448 · Cited by 119

MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors

Cros, J. F., Hentic, O., Rebours, V., Zappa, M., Gille, N., Théou–Anton, N., Vernerey, D., Maire, F., Lévy, P., Bédossa, P., et al. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0117 · Cited by 112

Mutations in chromatin machinery and pediatric high-grade glioma

Lulla, R. R., Saratsis, A. M., & Hashizume, R. (2016) · Science Advances · doi:10.1126/sciadv.1501354 · Cited by 99

Impairment of Glioma Stem Cell Survival and Growth by a Novel Inhibitor for Survivin–Ran Protein Complex

Guvenc, H., Pavlyukov, M. S., Joshi, K., Kurt, H., Banasavadi‐Siddegowda, Y., Mao, P., Hong, C. S., Yamada, R., Kwon, C., Bhasin, D., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0647 · Cited by 94

Autophagy as a Potential Therapy for Malignant Glioma

Escamilla-Ramírez, Á., Castillo‐Rodríguez, R. A., Zavala-Vega, S., Jiménez‐Farfán, D., Anaya‐Rubio, I., Briseño, E., Palencia, G., Guevara, P., Cruz-Salgado, A., Sotelo, J., et al. (2020) · Pharmaceuticals · doi:10.3390/ph13070156 · Cited by 94

The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma

Pokorny, J. L., Calligaris, D., Gupta, S. K., Iyekegbe, D. O., Mueller, D. J., Bakken, K. K., Carlson, B. L., Schroeder, M. A., Evans, D. L., Lou, Z., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2588 · Cited by 91

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

Parrish, K. E., Cen, L., Murray, J., Calligaris, D., Kizilbash, S. H., Mittapalli, R. K., Carlson, B. L., Schroeder, M. A., Sludden, J., Boddy, A. V., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0553 · Cited by 93

In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing

Kreth, S., Limbeck, E., Hinske, L. C., Schütz, S. V., Thon, N., Hoefig, K. P., Egensperger, R., & Kreth, F. W. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1081-1 · Cited by 90

Mechanisms and clinical significance of histone deacetylase inhibitors: epigenetic glioblastoma therapy.

Lee, P., Murphy, B., Miller, R., Menon, V., Banik, N. L., Giglio, P., Lindhorst, S., Varma, A. K., Vandergrift, W. A., Patel, S. J., et al. (2015) · PubMed · Cited by 83

Diffuse intrinsic pontine glioma: molecular landscape and emerging therapeutic targets

Aziz‐Bose, R., & Monje, M. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000577 · Cited by 82

Dacarbazine in Solitary Fibrous Tumor: A Case Series Analysis and Preclinical Evidence vis-à-vis Temozolomide and Antiangiogenics

Stacchiotti, S., Tortoreto, M., Bozzi, F., Tamborini, E., Morosi, C., Messina, A., Libertini, M., Palassini, E., Cominetti, D., Negri, T., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0776 · Cited by 79

Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts

Gupta, S. K., Mladek, A. C., Carlson, B. L., Boakye‐Agyeman, F., Bakken, K. K., Kizilbash, S. H., Schroeder, M. A., Reid, J. M., & Sarkaria, J. N. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3446 · Cited by 81

miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma

Li, Y., Liu, Y., Ren, J. F., Deng, S., Yi, G., Guo, M., Shu, S., Zhao, L., Peng, Y.-P., & Qi, S. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2835-3 · Cited by 74

Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins

Kitange, G. J., Mladek, A. C., Schroeder, M. A., Pokorny, J. C., Carlson, B. L., Zhang, Y., Nair, A., Lee, J., Yan, H., Decker, P. A., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.045 · Cited by 73

Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma

del Alcazar, C. R. G., Todorova, P. K., Habib, A. A., Mukherjee, B., & Burma, S. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0125 · Cited by 73

Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells

Banelli, B., Daga, A., Forlani, A., Allemanni, G., Marubbi, D., Pistillo, M. P., Profumo, A., & Romani, M. (2017) · Oncotarget · doi:10.18632/oncotarget.16820 · Cited by 73

Targeting of Histone Demethylases KDM5A and KDM6B Inhibits the Proliferation of Temozolomide-Resistant Glioblastoma Cells

Romani, M., Daga, A., Forlani, A., Pistillo, M. P., & Banelli, B. (2019) · Cancers · doi:10.3390/cancers11060878 · Cited by 73

Interplay of m6A and histone modifications contributes to temozolomide resistance in glioblastoma

Li, F., Chen, S., Yu, J., Gao, Z., Sun, Z., Yang, Y., Long, T., Zhang, C., Li, Y., Pan, Y., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.553 · Cited by 69

ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells

Nadkarni, A., Shrivastav, M., Mladek, A. C., Schwingler, P. M., Grogan, P. T., Chen, J., & Sarkaria, J. N. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0979-0 · Cited by 70

Potential New Therapies for Pediatric Diffuse Intrinsic Pontine Glioma

Long, W., Yang, Y., Chen, S., Cao, Q., Zhao, W., & Liu, Q. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00495 · Cited by 71

Immunohistochemical profiles of I DH 1, MGMT and P 53: Practical significance for prognostication of patients with diffuse gliomas

Ogura, R., Tsukamoto, Y., Natsumeda, M., Isogawa, M., Aoki, H., Kobayashi, T., Yoshida, S., Okamoto, K., Takahashi, H., Fujii, Y., et al. (2015) · Neuropathology · doi:10.1111/neup.12196 · Cited by 64

Combination LSD1 and HOTAIR-EZH2 inhibition disrupts cell cycle processes and induces apoptosis in glioblastoma cells

Zhao, J., Jin, W., Yi, K., Wang, Q., Zhou, J., Tan, Y., Xu, C., Xiao, M., Hong, B., Xu, F., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105764 · Cited by 65

Triacetin‐based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma

Tsen, A. R., Long, P. M., Driscoll, H. E., Davies, M. T., Teasdale, B., Penar, P. L., Pendlebury, W. W., Spees, J. L., Lawler, S. E., Viapiano, M. S., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28465 · Cited by 62

An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?

Teraiya, M., Perreault, H., & Chen, V. C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1166207 · Cited by 66

MGMT in TMZ-based glioma therapy: Multifaceted insights and clinical trial perspectives

Shaw, R., Basu, M., Karmakar, S., & Ghosh, M. K. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2024.119673 · Cited by 62

Acetate as a Metabolic and Epigenetic Modifier of Cancer Therapy

Jaworski, D. M., Namboodiri, A. M. A., & Moffett, J. R. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25305 · Cited by 63

Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma

Nie, E., Miao, F., Jin, X., Wu, W., Zhou, X., Zeng, A., Yu, T., Zhi, T., Shi, Z., Wang, Y., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0596-2 · Cited by 58

Pediatric Diffuse Midline Gliomas: An Unfinished Puzzle

Ruscio, V. D., Baldo, G. D., Fabozzi, F., Vinci, M., Cacchione, A., de Billy, E., Megaro, G., Carai, A., & Mastronuzzi, A. (2022) · Diagnostics · doi:10.3390/diagnostics12092064 · Cited by 60

Understanding and Targeting Alkylator Resistance in Glioblastoma

Wick, W., & Platten, M. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0918 · Cited by 51

A Review of Approaches to Potentiate the Activity of Temozolomide against Glioblastoma to Overcome Resistance

Karve, A. S., Desai, J. M., Gadgil, S. N., Dave, N., Wise-Draper, T. M., Gudelsky, G. A., Phoenix, T. N., Dasgupta, B., Yogendran, L., Sengupta, S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063217 · Cited by 52

Mesenchymal Stem Cells Cancel Azoxymethane-Induced Tumor Initiation

Nasuno, M., Arimura, Y., Nagaishi, K., Isshiki, H., Onodera, K., Nakagaki, S., Watanabe, S., Idogawa, M., Yamashita, K., Naishiro, Y., et al. (2013) · Stem Cells · doi:10.1002/stem.1594 · Cited by 51

RBBP4 regulates the expression of the Mre11-Rad50-NBS1 (MRN) complex and promotes DNA double-strand break repair to mediate glioblastoma chemoradiotherapy resistance

Li, J., Song, C., Gu, J., Li, C., Zang, W., Shi, L., Chen, L., Zhu, L., Zhou, M., Wang, T., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216078 · Cited by 47

Epigenetic alternations and cancer chemotherapy response

Lv, J., Hu, L., Zhuo, W., Zhang, C., Zhou, H., & Fan, L. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2951-0 · Cited by 46

Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines

Anderson, J. C., Duarte, C. W., Welaya, K. Y., Rohrbach, T. D., Bredel, M., Yang, E. S.-H., Choradia, N., Thottassery, J. V., Gillespie, G. Y., Bonner, J. A., et al. (2014) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2014.04.010 · Cited by 47

Epigenetics of Most Aggressive Solid Tumors: Pathways, Targets and Treatments

Martínez‐Useros, J., Martin-Galan, M., Florez-Cespedes, M., & García‐Foncillas, J. (2021) · Cancers · doi:10.3390/cancers13133209 · Cited by 46

The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance

Hersh, D. S., Harder, B. G., Roos, A., Peng, S., Heath, J. E., Legesse, T. B., Kim, A. J., Woodworth, G. F., Tran, N. L., & Winkles, J. A. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy063 · Cited by 43

A multifaceted review of temozolomide resistance mechanisms in glioblastoma beyond O-6-methylguanine-DNA methyltransferase

Poon, W. S., Woo, P. M., Li, Y., Chan, A. Y., Ng, S. P., Loong, H. H.-F., Chan, D. M., & Wong, G. K. C. (2019) · Glioma · doi:10.4103/glioma.glioma_3_19 · Cited by 48

Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways

Sampson, V. B., Vetter, N. S., Kamara, D. F., Collier, A. B., Gresh, R. C., & Kolb, E. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142704 · Cited by 42

Late autophagy inhibitor chloroquine improves efficacy of the histone deacetylase inhibitor SAHA and temozolomide in gliomas

Gonçalves, R. M., Agnes, J. P., Delgobo, M., de Souza, P. O., Thomé, M. P. M., Heimfarth, L., Lenz, G., Moreira, J. C. F., & Zanotto‐Filho, A. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.03.015 · Cited by 42

Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells

Harder, B. G., Peng, S., Sereduk, C., Sodoma, A. M., Kitange, G. J., Loftus, J. C., Sarkaria, J. N., & Tran, N. L. (2019) · Molecular Medicine · doi:10.1186/s10020-019-0116-z · Cited by 41

Efficacy of the MDM2 inhibitor SAR405838 in glioblastoma is limited by poor distribution across the blood-brain barrier

Kim, M., Ma, D. J., Calligaris, D., Zhang, S., Feathers, R. W., Vaubel, R. A., Meaux, I., Mladek, A. C., Parrish, K. E., Jin, F., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0600 · Cited by 39

Glioblastomas located in proximity to the subventricular zone (SVZ) exhibited enrichment of gene expression profiles associated with the cancer stem cell state

Steed, T., Treiber, J. M., Taha, B. R., Engin, H. B., Carter, H. K., Patel, K. S., Dale, A. M., Carter, B. S., & Chen, C. C. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03550-4 · Cited by 38

Identification of differentially expressed genes regulated by transcription factors in glioblastomas by bioinformatics analysis

Wei, B., Wang, L., Du, C., Hu, G., Wang, L., Jin, Y., & Kong, D. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.3094 · Cited by 37

ATM inhibition exploits checkpoint defects and ATM-dependent double strand break repair in TP53-mutant glioblastoma

Laverty, D. J., Gupta, S. K., Bradshaw, G. A., Hunter, A. S., Carlson, B. L., Calmo, N. M., Chen, J., Tian, S., Sarkaria, J. N., & Nagel, Z. D. (2024) · Nature Communications · doi:10.1038/s41467-024-49316-8 · Cited by 43

Upregulation of miR-125b, miR-181d, and miR-221 Predicts Poor Prognosis in MGMT Promoter-Unmethylated Glioblastoma Patients

Chen, Y., Ho, H., Lin, S., Ho, T. D.-H., & Hsu, C. (2018) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqy008 · Cited by 36

Ablation of neuropilin-1 improves the therapeutic response in conventional drug-resistant glioblastoma multiforme

Angom, R. S., Mondal, S. K., Wang, F., Madamsetty, V. S., Wang, E., Dutta, S. K., Gulani, Y., Sarabia-Estrada, R., Sarkaria, J. N., Quiñones‐Hinojosa, A., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01462-1 · Cited by 36

Molecular Pathways Implicated in Radioresistance of Glioblastoma Multiforme: What Is the Role of Extracellular Vesicles?

Burko, P., D’Amico, G., Miltykh, I. S., Scalia, F., de Macario, E. C., Macario, A. J. L., Giglia, G., Cappello, F., & Bavisotto, C. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054883 · Cited by 37

Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas

Chiang, M., Chou, P., Wang, W., Sze, C., & Chang, N. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00043 · Cited by 34

MGMT Promoter Methylation Correlates with an Overall Survival Benefit in Chinese High-Grade Glioblastoma Patients Treated with Radiotherapy and Alkylating Agent-Based Chemotherapy: A Single-Institution Study

Shen, D., Liu, T., Lin, Q., Lu, X., Wang, Q., Lin, F., & Mao, W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107558 · Cited by 32

Cancer Epigenetics: Mechanisms and Crosstalk of a HDAC Inhibitor, Vorinostat

Stephanie Huang, R. (2013) · Chemotherapy Open access · doi:10.4172/2167-7700.1000111 · Cited by 30

Targeting of histone deacetylases in brain tumors

Ecker, J., Witt, O., & Milde, T. (2013) · CNS Oncology · doi:10.2217/cns.13.24 · Cited by 30

High expression of MKP1/DUSP1 counteracts glioma stem cell activity and mediates HDAC inhibitor response

Arrizabalaga, O., Moreno‐Cugnon, L., Auzmendi-Iriarte, J., Aldaz, P., de Cáceres, I. I., Garros-Regulez, L., Moncho-Amor, V., Torres-Bayona, S., Pernía, O., Pintado‐Berninches, L., et al. (2017) · Oncogenesis · doi:10.1038/s41389-017-0003-9 · Cited by 31

Contemporary murine models in preclinical astrocytoma drug development

McNeill, R. S., Vitucci, M., Wu, J., & Miller, C. R. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou288 · Cited by 31

Targeting Epigenetic Pathways in the Treatment of Pediatric Diffuse (High Grade) Gliomas

Vanan, M., Underhill, D. A., & Eisenstat, D. D. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0514-2 · Cited by 29

Molecular imaging HDACs class IIa expression-activity and pharmacologic inhibition in intracerebral glioma models in rats using PET/CT/(MRI) with [18F]TFAHA

Laws, M. T., Bonomi, R. E., Kamal, S., Gelovani, D. J., Llaniguez, J. T., Potukutchi, S., Lu, X., Mangner, T. J., & Gelovani, J. G. (2019) · Scientific Reports · doi:10.1038/s41598-019-40054-2 · Cited by 29

RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma

Mladek, A. C., Yan, H., Tian, S., Decker, P. A., Burgenske, D. M., Bakken, K. K., Hu, Z., He, L., Connors, M. A., Carlson, B. L., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac051 · Cited by 29

Epigenetic targeting of glioma stem cells: Short-term and long-term treatments with valproic acid modulate DNA methylation and differentiation behavior, but not temozolomide sensitivity

Riva, G., Butta, V., Cilibrasi, C., Baronchelli, S., Redaelli, S., Dalprà, L., Lavitrano, M., & Bentivegna, A. (2016) · Oncology Reports · doi:10.3892/or.2016.4665 · Cited by 30

Fluorescent reporter assays provide direct, accurate, quantitative measurements of MGMT status in human cells

Nagel, Z. D., Beharry, A. A., Mazzucato, P., Kitange, G. J., Sarkaria, J. N., Kool, E. T., & Samson, L. D. (2019) · PLoS ONE · doi:10.1371/journal.pone.0208341 · Cited by 28

EPIC-0628 abrogates HOTAIR/EZH2 interaction and enhances the temozolomide efficacy via promoting ATF3 expression and inhibiting DNA damage repair in glioblastoma

Yang, E., Hong, B., Wang, Y., Wang, Q., Zhao, J., Cui, X., Wu, Y., Yang, S., Su, D., Liu, X., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216812 · Cited by 27

Prognosis of glioblastoma with faint MGMT methylation-specific PCR product

Hsu, C., Ho, H., Lin, S., Chang‐Chien, Y., Chen, M.-H., Hsu, S. P. C., Yen, Y., Guo, W.-Y., & Ho, D. M. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1701-1 · Cited by 27

Correlation Between Tumor Location and Clinical Properties of Glioblastomas in Frontal and Temporal Lobes

Li, H., Sun, C., He, M., Yin, L.-C., Du, H.-G., & Zhang, J. (2018) · World Neurosurgery · doi:10.1016/j.wneu.2018.01.055 · Cited by 27

Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth

Ramirez, Y. P., Mladek, A. C., Phillips, R. M., Gynther, M., Rautio, J., Ross, A. H., Wheelhouse, R. T., & Sakaria, J. N. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0113 · Cited by 27

Characterization of EGFR-reprogrammable temozolomide-resistant cells in a model of glioblastoma

Gong, L., Yin, Y., Cheng, C., Wan, Q., Xia, D., Wang, M., Pu, Z., Zhang, B., & Zou, J. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01230-y · Cited by 25

Metabolic Effects of Known and Novel HDAC and SIRT Inhibitors in Glioblastomas Independently or Combined with Temozolomide

Čuperlović‐Culf, M., Touaibia, M., St‐Cœur, P., Poitras, J., Morin, P., & Culf, A. S. (2014) · Metabolites · doi:10.3390/metabo4030807 · Cited by 24

Small Molecule Inhibitors in Adult High-Grade Glioma: From the Past to the Future

Huang, W., Hao, Z., Mao, F., & Guo, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.911876 · Cited by 23

Role of miRNAs in Treatment Response and Toxicity of Childhood Acute Lymphoblastic Leukemia

Umerez, M., García‐Obregón, S., Martín‐Guerrero, I., Astigarraga, I., Gutiérrez-Camino, Á., & García‐Orad, Á. (2018) · Pharmacogenomics · doi:10.2217/pgs-2017-0164 · Cited by 22

Critical appraisal of MGMT in digestive NET treated with alkylating agents

de Mestier, L., Couvelard, A., Blažević, A., Hentic, O., de Herder, W. W., Rebours, V., Paradis, V., Ruszniewski, P. B., Hofland, L. J., & Cros, J. F. (2020) · Endocrine Related Cancer · doi:10.1530/erc-20-0227 · Cited by 22

Revolutionizing Brain Tumor Care: Emerging Technologies and Strategies

Nguyen, T., Greene, L. A., Mnatsakanyan, H., & Badr, C. (2024) · Biomedicines · doi:10.3390/biomedicines12061376 · Cited by 13

The MGMT promoter single-nucleotide polymorphism rs1625649 had prognostic impact on patients with MGMT methylated glioblastoma

Hsu, C., Ho, H., Lin, S., Ho, T. D.-H., & Ho, D. M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186430 · Cited by 21

Chromatin insulation dynamics in glioblastoma: challenges and future perspectives of precision oncology

Sesé, B., Ensenyat-Méndez, M., Íñiguez-Muñoz, S., Llinàs‐Arias, P., & Marzese, D. M. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01139-w · Cited by 20

Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma

Daniel, P. M., Meehan, B., Sabri, S., Jamali, F., Sarkaria, J. N., Choi, D., Garnier, D., Kitange, G. J., Glennon, K. I., Paccard, A., et al. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac076 · Cited by 22

An in vivo model of glioblastoma radiation resistance identifies long noncoding RNAs and targetable kinases

Stackhouse, C. T., Anderson, J. C., Yue, Z., Nguyen, T. M., Eustace, N. J., Langford, C. P., Wang, J., Rowland, J. R., Xing, C., Mikhail, F. M., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.148717 · Cited by 23

Comparative Assessment of 4 Methods to Analyze MGMT Status in a Series of 121 Glioblastoma Patients

Hsu, C., Ho, H., Lin, S., Chen, M., Hsu, S. P., Yen, Y., Guo, W., & Ho, D. M. (2016) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000331 · Cited by 21

Temozolomide Resistance: A Multifarious Review on Mechanisms Beyond O-6-Methylguanine-DNA Methyltransferase

Rao, V., Kumar, G., Vibhavari, R. J. A., Nandakumar, K., Thorat, N. D., Chamallamudi, M. R., & Kumar, N. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220404180944 · Cited by 20

SGEF Is Regulated via TWEAK/Fn14/NF-κB Signaling and Promotes Survival by Modulation of the DNA Repair Response to Temozolomide

Ensign, S. P. F., Roos, A., Mathews, I. T., Dhruv, H., Tuncali, S., Sarkaria, J. N., Symons, M. H., Loftus, J. C., Berens, M. E., & Tran, N. L. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0183 · Cited by 19

Subclonal evolution and expansion of spatially distinct THY1-positive cells is associated with recurrence in glioblastoma

Al‐Holou, W. N., Wang, H., Ravikumar, V., Shankar, S., Oneka, M. D., Fehmi, Z., Verhaak, R. G. W., Kim, H., Pratt, D. W., Camelo-Piragua, S. I., et al. (2023) · Neoplasia · doi:10.1016/j.neo.2022.100872 · Cited by 20

Introducing HDAC-Targeting Radiopharmaceuticals for Glioblastoma Imaging and Therapy

Everix, L., Seane, E. N., Ebenhan, T., Goethals, I., & Bolcaen, J. (2023) · Pharmaceuticals · doi:10.3390/ph16020227 · Cited by 19

Knockdown of SALL4 expression using RNA interference induces cell cycle arrest, enhances early apoptosis, inhibits invasion and increases chemosensitivity to temozolomide in U251 glioma cells

Zhang, L., Yan, Y., Jiang, Y., Qian, J., Jiang, L., Hu, G., Lu, Y., & Luo, C. (2017) · Oncology Letters · doi:10.3892/ol.2017.6722 · Cited by 19

Effects of Culture Condition on Epigenomic Profiles of Brain Tumor Cells

Cox, M. C., Deng, C., Naler, L. B., Lu, C., & Verbridge, S. S. (2019) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.9b00161 · Cited by 18

Enhancing Temozolomide (TMZ) chemosensitivity using CRISPR-dCas9-mediated downregulation of O6-methylguanine DNA methyltransferase (MGMT)

Yousefi, Y., Nejati, R., Eslahi, A., Alizadeh, F. L., Farrokhi, S., Asoodeh, A., & Mojarrad, M. (2024) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04708-0 · Cited by 17

MEN1 Deficiency‐Driven Activation of the β‐Catenin‐MGMT Axis Promotes Pancreatic Neuroendocrine Tumor Growth and Confers Temozolomide Resistance

Xu, J., Lou, X., Wang, F., Zhang, W., Xu, X., Ye, Z., Zhuo, Q., Wang, Y., Jing, D., Fan, G., et al. (2024) · Advanced Science · doi:10.1002/advs.202308417 · Cited by 17

Deep learning MRI signature to predict survival and treatment benefit from temozolomide in IDH-wildtype glioblastoma

You, H., Zhao, Y., Sun, Q., Wu, W., Lv, X., Chen, Y., Zhang, H., & Li, Z. (2023) · Displays · doi:10.1016/j.displa.2023.102399 · Cited by 15

Genetic and epigenetic landscape of O6-methylguanine-DNA methyltransferase (MGMT): implications for DNA repair and cancer therapeutics

Singh, S., Nema, R., Banerjee, M., & Kushwah, A. S. (2025) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2025.1002335 · Cited by 14

Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies

Liu, G., Qiu, Y., Zhang, P., Chen, Z., Chen, S., Huang, W., Wang, B., Yu, X., & Guo, D. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091762 · Cited by 14

MGMT Epigenetics: The Influence of Gene Body Methylation and Other Insights Derived from Integrated Methylomic, Transcriptomic, and Chromatin Analyses in Various Cancer Types

Bacolod, M. D., & Barany, F. (2021) · Current Cancer Drug Targets · doi:10.2174/1568009621666210203111620 · Cited by 13

Abstract 5905: Sp1 acetylation associates with stemness characteristics in temozolomide-resistant glioblastoma

Chuang, J., Hsu, C., Chang, K., & Chang, W. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-5905 · Cited by 5

GENE-20. A NOVEL K-M ENHANCER REGULATES TEMOZOLOMIDE RESISTANCE AND TUMOR GROWTH IN GLIOBLASTOMA

Chen, X., Zhang, M., Gan, H., Lee, J., Fang, D., Kitange, G. J., He, L., Hu, Z., Zhang, Z., & Sarkaria, J. N. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy148.446

Identification of TMZ resistance‐associated histone post‐translational modifications in glioblastoma using multi‐omics data

Ye, L., Gu, L., Wang, Y., Xing, H., Li, P., Guo, X.-P., Wang, Y., & Ma, W. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14649 · Cited by 14

Chemical screens identify HDAC6 as an epigenetic vulnerability in acquired Temozolomide-resistant models of glioblastomaPreprint

Aksu, F., Cevatemre, B., Degirmenci, N. P., Kala, E. Y., Uçku, D., Philpott, M., Cribbs, A. P., Dunford, J. E., Oppermann, U. C. T., Açılan, C., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.07.723296

Interplay of m6A and histone modifications contributes to temozolomide resistance in glioblastoma

Li, F., Chen, S., Yu, J., Gao, Z., Sun, Z., Yang, Y., Long, T., Zhang, C., Li, Y., Pan, Y., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.553 · Cited by 69